Share on facebook Share on Twitter Share on Google Plus Share This

Cancer Center

Back to Results

Andrew Evens, DO, MSc


Programs + Specialties
Research Interests The discovery and testing of novel and targeted therapeutic agents in lymphoma, lymphoma biology and signal transduction pathways, the prognosis and treatment of lymphomas, lymphoma epidemiology, lymphoma health outcomes, including pharmacovigilance
Training + Education Chicago College of Osteopathic Medicine; Lutheran General Hospital, Illinois; Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center
Board Certifications Hematology, Medical Oncology
NPI # 1265468110
Gender Male
Accepted Insurances View Accepted Insurances at Tufts MC + Floating Hospital

Locations + Directions

Tufts Medical Center
South Building, 8th Floor
800 Washington St.
Box 245
Boston, MA 02111
Phone #: 617-636-6227
Fax #: 617-636-7060

Honors + Awards

2016, ASCO Educational Session; PET-Directed Therapy for Early-Stage Hodgkin Lymphoma; ASCO Annual Meeting
2016, Nominated to Fellowship of the American College of Physicians (FACP)
2015, Named the Chan Soon-Shiong Endowed Scholar in Precision Medicine at Tufts Medical Center, Boston, MA
2015, Advisory Panel Member to Vice President Joseph Biden; Naval Observatory, Washington, DC; December 1st, 2015
2014, Nominated to the Scientific Advisory Board, for Lymphoma Research Foundation (LRF)
2014, ASH Educational Session; The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. ASH Annual Meeting
2013, Meet the Professor (Hodgkin lymphoma): Lugano ICML; and ASH Annual Meeting
2008 – 2009, Teaching Attending of the Year, Division of Hematology/Oncology, Northwestern University
2008 – 2009, Annual Excellence in Teaching Award, Department of Medicine, Northwestern University
2005, Compassionate Care Annual Award, The Woman’s Board of Northwestern Memorial Hospital
2002, Translational Research Award (most outstanding research presentation), ECOG’s Young Investigators Clinical Scientist Symposium, National ECOG Meeting, Miami, FL
1998, First Place, Clinical Vignette for ACP Illinois Chapter Regional Meeting, Chicago, IL
1996, Intern of the Year (class size: 35), Internal Medicine, Lutheran General, Park Ridge, IL
1994, Sigma Sigma Phi, National Osteopathic Honor Society, Downers Grove, IL
1991, Magna Cum Laude, Biochemistry, Saint Joseph’s College, Rensselaer, IN
1989, Bill Bradley Academic All-American, NCAA College Basketball

Publications + National Presentations

1. Evens AM, Spies WG, Helenowski IB, Patton D, Spies S, Jovanovic BD, Miyata S, Hamilton E, Variakojis D, Chen J, Naumovski L, Rosen ST, Winter JN, Miller RA, Gordon LI. The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y] Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial. Clinical Cancer Research. 2009; 15:6462-71. PMID: 19825958

2. Evens AM, David KA, Helenowski IB, Nelson B, Kaufman D, Kircher S, Gimelfarb, Hattersley E, Mauro L, Jovanovic B, Chadburn AM, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory SA, Gordon LI, Shammo JM, Smith S, Smith SM. Multicenter Analysis of 80 Solid Organ Transplant Recipients with Posttransplantation Lymphoproliferative Disease (PTLD): Outcomes and Prognostic Factors in the Modern Era. Journal of Clinical Oncology. 2010; 28:1038-46. PMID: 20085936

3. Evens AM, Sehn LH, Farinha P, Nelson BP, Raji A, Lu Y, Brakman A, Parimi V, Winter JN, Schumacker PT, Gascoyne RD, Gordon LI. Hypoxia-Inducible Factor-1 Alpha (HIF-1α) Expression Predicts Superior Survival in Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP. Journal of Clinical Oncology. 2010; 28:1017-24. PMID: 20048181

4. Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012; 119:692-5. PMID: 22117038

5. Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW. Stem Cell Transplantation for Follicular Lymphoma Relapsed/Refractory After Prior Rituximab: A Comprehensive Analysis from the NCCN Lymphoma Outcomes Project. Cancer. 2013; 119(20):3662-71. PMID: 23921646

6. Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Dagan LN, Abdallah R, Kroll A, Yarber JL, Sandoval J, Parker LM, Gordon LI, Blum KA, Flowers C, Leonard JP, Habermann TM, Bartlett NL. Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis. Journal of Clinical Oncology, 2013; 31:4132-9.PMID: 24043736

7. Ravi D, Bhalla S, Gartenhaus RB, Crombie J, Kandela I, Sharma J, Mazar A, Evens AM. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models. Clinical Cancer Research. 2014; 20:6023-33. PMID: 25316819

8. Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Clinical Cancer Research. 2016; 22:1059-66. PMID: 26482040

9. Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, Kritharis A, Kandela I, Hlatky L, Sitkovsky MV, Mazar A, Gartenhaus RB, Evens AM. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma. Cancer Research. 2016; 76:3319-31. PMID: 26988986

10. Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016; 128:2199-2205. PMID: 27601462


Following graduation with honors from the Chicago College of Osteopathic Medicine at Midwestern University, Dr. Evens completed his Internal Medicine residency at Lutheran General Hospital and he served an additional year as Chief Medical Resident. Dr. Evens subsequently completed his Hematology/Oncology fellowship at Northwestern University Feinberg School of Medicine and The Robert H. Lurie Comprehensive Cancer Center (RHLCCC). During fellowship, Dr. Evens also completed a Masters of Science in Clinical Investigation at Northwestern University. He is board certified in Hematology and Medical Oncology. Dr. Evens was a faculty member in the Division of Hematology/Oncology at Northwestern University and the RHLCCC through December 2010. He subsequently was a faculty member at the University of Massachusetts Medical School and the UMass Memorial Cancer Center (UMMCC) where he served as the Deputy Director of the UMMCC for Clinical and Translational Research. At Tufts MC, Dr. Evens is the Director of the Lymphoma Program.

Dr. Evens is a National and International expert in the biology, prognosis, and treatment of Non-Hodgkin lymphoma and Hodgkin disease/lymphoma. His clinical and research interests are dedicated wholly towards lymphoma, including bone marrow/stem cell transplantation (SCT). Over the past 10 years, Dr. Evens has been the principal investigator for >60 lymphoma clinical trials that have included phase I, II, and III studies- a number of which have been investigator-initiated clinical trials studying novel therapeutic agents for the treatment of lymphoma. Dr. Evens also maintains an active translational lymphoma laboratory studying lymphoma biology, signal transduction pathways, free radical-mediated biology, and the development of novel targeted agents for the treatment of lymphoma.

His work has been funded by the National Institutes of Health (NIH) and the National Cancer Institutes (NCI), including a prior 5-year K23 grant entitled 'Targeting the Mitochondria to Treat Lymphoma' and a currently funded R01 entitled 'MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm'. Dr. Evens has presented >120 research abstracts at National and International meetings (including >20 peer reviewed oral research presentations), written >10 book chapters, and he has published >110 manuscripts (including >75 original research articles) with a particular emphasis on the biology, prognosis, and treatment of lymphoma in a number of journals including the New England Journal of Medicine, Journal of American Medical Association, Blood, Journal of Clinical Oncology, Clinical Cancer Research, British Journal of Haematology, and Annals of Internal Medicine. Additionally, Dr. Evens is an Associate Editor for the British Journal of Haematology and on the Editorial Board of the Journal of Clinical Oncology.

Dr. Evens is a primary member of the select Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and he is Chair of the Hematology Review Panel (R01) for the NIH/NCI VA Scientific Merit Review. He is also a “Core Member” of the Eastern Cooperative Oncology Group (ECOG) Lymphoma committee. Further, he is the ECOG Principal Investigator for several National clinical trials including high-risk follicular lymphoma (E2408, NCT01216683) and newly diagnosed (S0816) Hodgkin’s disease/lymphoma. Dr. Evens is also involved in several collaborations with investigators throughout the New England region, nationally, and internationally that include research on Hodgkin lymphoma, post-transplant lymphomproliferative disorders (PTLD), and epidemiological lymphoma research. He co-chairs an annual Chicago Lymphoma Symposium ( and he chairs a regional lymphoma collaborative educational effort through the Lymphoma Research Foundation (New England Lymphoma Rounds).

Professional Memberships

American Society of Hematology (ASH)
American Society of Clinical Oncology (ASCO)
Eastern Cooperative Oncology Group (ECOG): Lymphoma ‘Core Committee’ Member
National Comprehensive Cancer Network (NCCN), Hodgkin disease/lymphoma, primary member
Non-Hodgkin’s lymphoma, secondary member (2007-2010)
Primary/voting member, ECOG Laboratory Science Advisory Committee
Primary/voting member, Developmental Therapeutics committee, ECOG
Clinical Trial Design & Development Working Group, Quantitative Imaging Network (QIN) with CTEP and NIH
Hodgkin Lymphoma Working Group member (NIH/NCI Steering Committee Subgroup)
Associate Editor, British Journal of Hematology
NantKwest QUILT - Quantitative Integrated Lifelong Trials
Cancer MoonShot 2020
Founding Institution and Advisory Board
Member, InterLymph Lifestyle & Environment Working Group, NIH and NCI

News, Media + Videos

Dr. Andrew Evens

Dr. Evens to chair annual symposium for Lymphoma Research Foundation

Read more about Dr. Evens' role and forum topics
Myeloma and amyloidosis expert Ray Comenzo talks with a patient in Boston at Tufts Medical Center.

Tufts Medical Center sponsors national ‘RAIN’ trial for rare blood cancer

Tufts Medical Center sponsors national ‘RAIN’ trial for rare blood cancer - Read More
A drawing of a care team member for Tufts Medical Center in downtown Boston, MA.

Our take: Recent FDA study shows breast implants can be associated with rare type of lymphoma.

Learn more about the study
New England Cancer Specialists and Tufts Medical Center form partnership to advance cancer care in New England.

New England Cancer Specialists and Tufts Medical Center form partnership to advance cancer care in New England.

Partnership to advance cancer care